Literature DB >> 19236184

Chemotherapy of malignant pleural mesothelioma.

Pietro Bertino1, Michele Carbone, Harvey Pass.   

Abstract

BACKGROUND: Owing to worldwide use of asbestos during the past century, the global incidence of mesothelioma is still increasing. Although the outcome for patients remains poor, there has been definite progress in the systemic treatment of this disease within the past 5 years.
OBJECTIVE: By examining the clinical trials performed and the role of novel emerging agents, this review aims to provide an 'expert opinion' on evidences that validate chemotherapy as current 'standard of care' for inoperable mesothelioma.
METHODS: Relevant literature about clinical trials was reviewed using a PubMed search and other relevant data about novel therapeutic approaches both established and in development.
CONCLUSION: The response rates achieved using chemotherapeutic treatments are higher than previous ones, and in the future may be improved by the use of combined and personalized therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19236184     DOI: 10.1517/14656560802631285

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

Review 1.  Malignant mesothelioma: facts, myths, and hypotheses.

Authors:  Michele Carbone; Bevan H Ly; Ronald F Dodson; Ian Pagano; Paul T Morris; Umran A Dogan; Adi F Gazdar; Harvey I Pass; Haining Yang
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

Review 2.  The role of interleukin-6 in malignant mesothelioma.

Authors:  Siti N Abdul Rahim; Gwo Y Ho; Jermaine I G Coward
Journal:  Transl Lung Cancer Res       Date:  2015-02

3.  Fowlpox-based survivin vaccination for malignant mesothelioma therapy.

Authors:  Pietro Bertino; Maddalena Panigada; Elisa Soprana; Valentina Bianchi; Sabrina Bertilaccio; Francesca Sanvito; Aaron H Rose; Haining Yang; Giovanni Gaudino; Peter R Hoffmann; Antonio Siccardi; Michele Carbone
Journal:  Int J Cancer       Date:  2013-02-25       Impact factor: 7.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.